Amgen: Regulatory Reform Must Not Tie The FDA’s Hands On Evaluating Biosimilarity
Biosimilars Executive Leah Christl Offers Amgen’s Perspective On The Need For Efficacy Trials
Christl says the FDA’s hands must not be tied by any changes to the agency’s approach to evaluating biosimilarity • Source: Shutterstock 
